Ubiquitination and Deubiquitination in Melanoma Research and Clinically Relevant Outcomes

Abstract

Malignant melanoma is one of the most invasive tumors with increasing mortality, low overall survival rates and limited effective therapeutic strategies. Ubiquitination is a post-translational protein modification, which is regulated by a series of ubiquitination-associated enzymes. Ubiquitination plays a critical role in diverse pathophysiological activities of cellular and participates in the pathogenesis of various cancers, including melanoma. This study aims to provide a conclusive of ubiquitination and deubiquitination, and their potential clinical application value in melanoma in the following aspects: melanoma pathogenesis-related components and processes in the ubuiquitin-proteasome system (UPS), ubiquitination in melanoma immunological microenvironment modulation, ubiquitination of key transcription factors in melanoma and melanoma therapeutic strategy via targeting the UPS.

Reading ADP-ribosylation signaling using chemical biology and interaction proteomics

“…One of the validated PAR readers, MKRN2, contains a signature RING ZF C3HC4 and exhibits E3 ligase activity (Shin et al, 2017). That protein has previously been implicated as a potential therapeutic target in melanoma (Guo and Zhang, 2020). The E3 ligase activity of RNF146/Iduna is stimulated by PAR binding (Kang et al, 2011).…”